FY2018 EPS Estimates for Tenax Therapeutics Inc. Decreased by Analyst (TENX)
Tenax Therapeutics Inc. (NASDAQ:TENX) – Analysts at Zacks Investment Research dropped their FY2018 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a research note issued to investors on Tuesday. Zacks Investment Research analyst J. Vandermosten now anticipates that the firm will post earnings of $0.71 per share for the year, down from their prior forecast of $0.86.
Shares of Tenax Therapeutics (NASDAQ:TENX) traded up 4.17% on Thursday, reaching $1.50. The company had a trading volume of 96,037 shares. The company’s 50-day moving average is $1.79 and its 200 day moving average is $2.34. The firm’s market capitalization is $42.18 million. Tenax Therapeutics has a 12 month low of $1.21 and a 12 month high of $3.40.
Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Thursday, November 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02.
Tenax Therapeutics Company Profile
Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity.
Receive News & Stock Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related stocks with our FREE daily email newsletter.